Ubyssey Online Kizhakkedathu said that one to three percent of the global population uses heparin . It is not only used for the regular treatment of cardiovascular disease such as venous or arterial thromboembolism but also in most surgeries and all dialysis procedures.
WhaTech In terms of the proposed/ongoing projects, however, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for ...
Virtual-Strategy Magazine (press release) THOROFARE, N.J., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the receipt of an initial ...
Digital Journal Most up-to-date research on "China Heparin Industry Report, 2014-2017" to its huge collection of research reports. Albany, NY -- (ReleaseWire) -- 12/12/2014 -- As the world's major heparin API producer and exporter, China boasts enormous raw materials, ...
The Pharmaceutical Journal The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for heparin sodium IV flush solution 100 IU/ml distributed by Kent Pharmaceuticals Ltd on behalf of Fannin (UK) Limited. This is due to an error on cartons ...
Newswise (press release) Newswise — Hamilton, ON (Nov. 18, 2014) – McMaster University researchers have found new evidence that suggests patients with a history of adver...
Philadelphia Business Journal (blog) "We believe China can be a very significant market for the Company's PIFA Heparin /PF4 Rapid Assay products," said Raymond F. Akers...
TCTMD The risks of MACE at 30 days (primary efficacy endpoint; death, MI, urgent TVR or TLR, or stroke) each were higher with unfractionated heparin , bivalirudin, and fondaparinux alone compared with unfractionated heparin plus GPI and LMWH plus GPI ... and more »
MedPage Today SAN FRANCISCO -- Treatment of deep vein thromboses (DVT) with the low-molecular-weight heparin tinzaparin (Innohep) lessened the risk of recurrent blood clots in cancer patients, along with significantly reducing symptomatic DVT and clinically relevant ...
MedPage Today "As the largest randomized, controlled trial on the treatment of thrombosis among cancer patients, this study reinforces clinical guidelines supporting the use of low-molecular-weight heparin instead of warfarin to prevent recurrent blood clots," Lee ...
